Skip Navigation
News
Contact
Toggle Navigation
Search:
Search Submit
Company
About
Our Team
Board of Directors
Science
Our Science
Radiotherapy-Induced Toxicity
Radiotherapy Anti-Cancer Efficacy
Scientific Publications
Pipeline
Our Pipeline
Patients & Caregivers
Investors
IR Home
Press Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
Shareholder Services
Contact
Publications
Phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer